New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
06 oct. 2018 07h30 HE
|
Biogen Inc.
NURTURE study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA)Study participants achieved motor milestones with 100...
Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
03 oct. 2018 07h30 HE
|
Biogen Inc.
CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s...
Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
02 oct. 2018 07h30 HE
|
Biogen Inc.
New research further supports the long-term efficacy and well-characterized safety of leading MS productsNovel data generation initiatives aim to improve outcomes and support the continued move toward...
Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
04 sept. 2018 07h30 HE
|
Biogen Inc.
CHARM study will evaluate IV glibenclamide for the prevention and treatment of severe cerebral edema in LHI, one of the most severe types of ischemic stroke with limited treatment optionsPrior studies...
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
25 juil. 2018 16h30 HE
|
Biogen Inc.
TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:BIIB) (Headquarters: Cambridge, Massachusetts,...
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2018
25 juil. 2018 10h30 HE
|
Biogen Inc.
TOKYO and CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq:BIIB) (Headquarters: Cambridge, Massachusetts,...
Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018
20 juil. 2018 08h39 HE
|
Biogen Inc.
CAMBRIDGE, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) today announced it will host a live webcast providing a Q&A session related to its Alzheimer’s disease investigational...
Data to be Presented From Biogen’s Alzheimer’s Disease Clinical Development Portfolio at the 2018 Alzheimer’s Association International Conference (AAIC)
18 juil. 2018 07h30 HE
|
Biogen Inc.
Ongoing Alzheimer’s disease research programs target possible causes of the disease through multiple modalitiesData to be presented from Alzheimer’s disease clinical development portfolio including...
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
05 juil. 2018 19h30 HE
|
Biogen Inc.
The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer’s disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta...
Biogen Exercises Option to Increase Ownership in Samsung Bioepis
28 juin 2018 16h06 HE
|
Biogen Inc.
Biogen will pay Samsung BioLogics approximately $700 million to increase its ownership in Samsung Bioepis to approximately 49.9%Transaction expected to close in the second half of 2018 CAMBRIDGE,...